Christopher Logothetis Pensacola Evening lecture

The improved understanding of cancer has resulted in significant improvements in patient outcomes. This is particularly relevant to prostate cancer, a heterogenous disease often accompanied by age-related vulnerabilities that must be considered to provide optimum care. Although patient care is improving, the pace of change is not equal to the rapid pace of scientific development. While potentially impactful observations are increasing exponentially, the health care model is expanding arithmetically.

The overall goal of our sustained effort is to build on the knowledge of prostate cancer to transition from reactive medicine to an anticipatory model of care. The elucidation of androgen signaling, prostate cancer molecular instability, and bone biology has created a new framework of prostate cancer that we are applying clinically. This collective effort may be applicable to other cancers and requires adjustments in the organization of health care with broader implications. We have thus concluded that in order to meaningfully apply the data and ensure proportional clinical benefit, we must transform the prevailing care model.

Dr. Christopher Logothetis serves as Director of the Prostate Cancer Research Program at MD Anderson. In addition, he is a Professor in The University of Texas MD Anderson Cancer Center in Houston. Dr. Logothetis has decades of research experience, of which the last 30 years have been largely focused on prostate cancer. His focus has been on developing therapies for prostate cancer and linking the underlying biology to the disease. He’s contributed to developing chemotherapy, bone targeted therapy, and molecularly-targeted therapies in specific subsets of patients in combination.

Dr. Logothetis served as Principal Investigator of the MD Anderson Cancer Center Prostate Cancer SPORE, a multidisciplinary, collaborative grant funded by the National Cancer Institute. He has keen insight into the potential for change and the importance of collaborations among colleagues in academic medicine, community physicians, and patient support and advocacy communities. Lastly, Dr. Logothetis has been appointed to the Board of Scientific Advisors of the NCI and is a member of the External Advisory Committee for the NCI-sponsored project to characterize the human cancer genome.

Know what’s Happening Next — before everyone else does.

Get App

Host or Publisher Florida Institute for Human & Machine Cognition